Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey

Circulation. 2017 Nov 7;136(19):1860-1862. doi: 10.1161/CIRCULATIONAHA.117.029102.
No abstract available

Keywords: cardiovascular diseases; hydroxymethylglutaryl-CoA reductase inhibitors; primary prevention; risk; waist-hip ratio.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / prevention & control*
  • Clinical Decision-Making*
  • Dyslipidemias / diagnosis
  • Dyslipidemias / drug therapy*
  • Dyslipidemias / epidemiology
  • Eligibility Determination
  • Evidence-Based Medicine / methods
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Nutrition Surveys
  • Patient Selection
  • Practice Guidelines as Topic
  • Primary Prevention / methods*
  • Primary Prevention / standards
  • Protective Factors
  • Randomized Controlled Trials as Topic / methods
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • United States / epidemiology

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors